NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) | Apply Online

Opportunity Summary:

The NIH Research Evaluation and Commercialization Hub (REACH) Awards (U01) opportunity, Funding Opportunity Number RFA-OD-14-005, was a National Institutes of Health (NIH) initiative designed to push promising biomedical discoveries out of the lab and closer to real-world use. The core idea was to fund a small number of proof-of-concept centers, referred to as REACH Hubs, that could consistently identify high-potential early-stage technologies and then provide the kind of structured support that helps those technologies become commercially viable products. NIH framed the goal in practical terms: accelerate translation into products that improve patient care and enhance health, rather than leaving innovations stalled at the prototype or publication stage.

The program emphasized building an institutional “engine” for translation rather than simply funding isolated projects. Each Hub was expected to establish infrastructure for scouting and selecting the most promising technologies within NIH’s mission areas, using some form of evaluation and prioritization process. Once a technology was selected, the Hub could provide direct support for product definition work. This included activities like feasibility studies, prototype development, and other proof-of-concept efforts that reduce technical risk and clarify what would be required for eventual commercialization. In other words, the funding was meant to bridge the gap between academic discovery and the early development milestones that investors, strategic partners, and industry typically expect before engaging.

A defining feature of REACH was the coordinated access to cross-functional expertise that early technologies usually lack. Hubs were expected to make expertise available not just on the science side, but also in areas that often determine whether a product ever reaches patients: regulatory strategy, reimbursement and market access considerations, business development, legal and intellectual property guidance, and disciplined project management. Beyond supporting specific technologies, NIH also wanted these Hubs to cultivate talent. The announcement explicitly called for skills development and hands-on experience in entrepreneurship, signaling that part of the deliverable was a stronger, more experienced community of biomedical innovators who understand commercialization pathways.

The funding mechanism was a cooperative agreement (U01), which generally implies substantial NIH involvement during the project period compared to a standard grant. Practically, this tends to mean the awardees should be prepared for active coordination with NIH program staff, milestone-driven progress expectations, and an emphasis on measurable translation outcomes. The activity categories listed for the opportunity span a very broad range of NIH-relevant domains (for example, cancer, cardiovascular disease, mental health, substance use, infectious disease, aging, genomics, minority health and health disparities, nursing research, and more), reinforcing that the program was not disease-specific. Instead, it targeted the commercialization “translation bottleneck” that cuts across biomedical fields.

The opportunity placed major weight on forming public-private partnerships and bringing in additional non-federal funding. NIH described this as critical to success, which is consistent with the program’s commercialization focus: external partners can provide market insight, customer discovery, product requirements, later-stage financing, and a path to licensing or startup formation. In effect, the REACH Hub model was intended to use NIH support as an initial catalytic investment, while building relationships and co-investment structures that could sustain a pipeline of translational projects beyond federal dollars alone.

From an administrative standpoint, the opportunity was posted April 25, 2014, with an original and current closing date of June 26, 2014, and it was archived July 27, 2014. NIH estimated total funding at $9,000,000, with an award ceiling of $1,000,000. The announcement indicated no cost sharing or matching requirement, although it still strongly encouraged (and arguably expected) leveraging non-federal resources through partnerships and other mechanisms.

Eligibility centered on institutions capable of operating a commercialization and proof-of-concept hub. Eligible applicants included public and state-controlled institutions of higher education and private institutions of higher education, along with specific categories of institutions emphasized in NIH eligibility language such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander-Serving Institutions (AANAPISIs). Non-U.S. (foreign) institutions were not eligible to apply, and non-U.S. components of U.S. organizations were also not eligible; however, foreign components as defined in the NIH Grants Policy Statement could be allowed in some circumstances.

In summary, REACH (U01) was structured to help institutions create a repeatable, milestone-driven pathway for moving early biomedical innovations toward commercialization. It combined selective technology sourcing, targeted proof-of-concept funding, integrated business and regulatory expertise, and entrepreneur training, while pushing awardees to develop strong public-private partnerships and attract additional non-federal support. The intended outcome was a more reliable pipeline of investable, translatable technologies positioned to become products that ultimately benefit patients.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Environment Food and Nutrition Health Income Security and Social Services

Next opportunity: Planning Grant for Global Infectious Disease Research Training Program (D71)

Previous opportunity: Recovery activities for the Karner Blue Butterfly (KBB) in Concord, NH. CFDA 15.650

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA OD 14 005

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA OD 14 005) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA OD 14 005", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.